

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc and Teva Canada Limited that the shortages for Sandoz Entacapone 200 mg Tablet (DIN 02380005) and Teva-Entacapone 200 mg Tablet (DIN 02380005) respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 25, 2020**.

ENTACAPONE

200 MG TABLET

00002380005	SANDOZ ENTACAPONE	SDZ	\$ 0.4010
00002375559	TEVA-ENTACAPONE	TEV	\$ 0.4010
00002243763	COMTAN	NOV	\$ 1.6685

Alberta Blue Cross has been advised by Sanis Health Inc., Sivem Pharmaceuticals ULC, and Pharmascience Inc. that the shortages for Irbesartan 75 mg Tablet (DIN 02372347), Irbesartan 75 mg Tablet (DIN 02385287) and pms-Irbesartan 75 mg Tablet (DIN 02317060) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 29, 2020**.

IRBESARTAN

75 MG TABLET

00002406098	AURO-IRBESARTAN	AUR	\$ 0.2281
00002372347	IRBESARTAN	SNS	\$ 0.2281
00002385287	IRBESARTAN	SIV	\$ 0.2281
00002418193	JAMP- IRBESARTAN	JPC	\$ 0.2281
00002422980	MINT- IRBESARTAN	MPI	\$ 0.2281
00002317060	PMS- IRBESARTAN	PMS	\$ 0.2281
00002406810	RAN- IRBESARTAN	RAN	\$ 0.2281
00002328461	SANDOZ- IRBESARTAN	SDZ	\$ 0.2281
00002316390	TEVA- IRBESARTAN	TEV	\$ 0.2281
00002237923	AVAPRO	SAV	\$ 1.2671

... continued from previous page

Product supply shortages addressed for Alberta Drug Benefit List (ADBL) continued

Alberta Blue Cross has been advised by Sanis Health Inc. and Sivem Pharmaceuticals ULC that the shortages for Irbesartan 150 mg Tablet (DIN 02372371) and Irbesartan 150 mg Tablet (DIN 02385295) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 29, 2020**.

IRBESARTAN

150 MG TABLET

00002406101	AURO-IRBESARTAN	AUR	\$ 0.2281
00002372371	IRBESARTAN	SNS	\$ 0.2281
00002385295	IRBESARTAN	SIV	\$ 0.2281
00002418207	JAMP-IRBESARTAN	JPC	\$ 0.2281
00002422999	MINT-IRBESARTAN	MPI	\$ 0.2281
00002317079	PMS-IRBESARTAN	PMS	\$ 0.2281
00002406829	RAN-IRBESAaN	RAN	\$ 0.2281
00002328488	SANDOZ IRBESARTAN	SDZ	\$ 0.2281
00002316404	TEVA-IRBESARTAN	TEV	\$ 0.2281
00002237924	AVAPRO	SAV	\$ 1.2671

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Teva Canada Limited that the shortages for Sandoz Prednisolone Acetate 1% Ophthalmic Suspension (DIN 01916203) and Teva-Prednisolone 1% Ophthalmic Suspension (DIN 00700401) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 8, 2020**.

PREDNISOLONE ACETATE

1 % OPHTHALMIC SUSPENSION

00001916203	SANDOZ PREDNISOLONE ACETATE	SDZ	\$ 1.9400
00000700401	TEVA-PREDNISOLON	TEV	\$ 1.9400
00000301175	PRED FORTE	ALL	\$ 5.2880

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php

